A presentation of the results followed by a Q&A session will be held on the same day at
For further information, please contact:
Brede Ellingsæter, CFO, brede.ellingseter@thormedical.no
About Thor Medical
Thor Medical is an emerging supplier of radionuclides, alpha particle emitters, for medical use in cancer therapy. Thor Medical has developed a proprietary technology for the manufacturing of alpha particle emitters from natural resources. Its novel production process requires no irradiation in nuclear reactors, and provides reliable, environmentally friendly supply of radionuclides for the radiopharmaceutical industry. The high energy deposition and the short range of alpha particles make it possible to eradicate cancer cells while minimizing damage to nearby healthy cells. Thor Medical is headquartered in
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
https://news.cision.com/thor-medical-asa/r/invitation-to-presentation-of-thor-medical-asa-s-first-half-results-2023,c3818750
(c) 2023 Cision. All rights reserved., source